Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 56 for “"factor IX"”.

  1. Novel carriers for oral delivery of hemophiliac factor IX

    … characterized by the deficiency of coagulation factor IX (FIX), rely on injection-based administration that cause pain and discomfort, leading to noncompliance and risk of subsequent bleeding episodes. A non-invasive protein replacement therapy using an oral delivery system can both overcome …

    texas Repository record for Novel carriers for oral delivery of hemophiliac factor IX (opens in a new tab)

  2. Production of recombinant human coagulation factor IX by transgenic pig

    … caused by deficiency in functional coagulation factor IX (FIX) and about 28,000 patients worldwide in 2012. And current treatment is restricted to protein-replacement therapy, which required FIX concentrates for patients' life-time. Approximately 1 billion units FIX were consumed in 2012. …

    nebraska Repository record for Production of recombinant human coagulation factor IX by transgenic pig (opens in a new tab)

  3. The transcriptional regulation of the gene for human clotting factor ix

    … for the response to AR and testosterone in the factor IX ARE, mutations were introduced at each position in the ARE, some spacer positions, and in some flanking positions. These mutant ARE sequences were then tested firstly, in vitro, in a competition gel mobility shift assay with an E.coli …

    oxford Repository record for The transcriptional regulation of the gene for human clotting factor ix (opens in a new tab)

  4. Electroporation of Mesenchymal Stem Cells for the Secretion of Factor IX

    … cord blood-derived mesenchymal stem cells with a Factor IX containing plasmid lead to the FIX protein being expressed for over 12 days <em>in vitro</em>. This optimized electroporation protocol has created a fast, easy, economic and efficient method for genetically modifying mesenchymal stem cells …

    mcmaster Repository record for Electroporation of Mesenchymal Stem Cells for the Secretion of Factor IX (opens in a new tab)

  5. The metal dependency of coagulation factor IX as it relates to its structure and function

    … disorder caused by deficiency in blood clotting factor IX (FIX). FIX circulates as a 55–57 kDa inactive precursor of the serine protease, FIXa. Activation results in the release of the activation peptide to generate an amino terminal light chain of Mr∼18,000 and a carboxyl terminal heavy chain of …

    nebraska Repository record for The metal dependency of coagulation factor IX as it relates to its structure and function (opens in a new tab)

  6. The N-terminal EGF Module of Coagulation factor IX. Studies of Calcium Binding and Module Interactions.

    Coagulation factor IX (FIX) is a vitamin K-dependent serine protease zymogen that circulates in plasma. Defects in FIX cause the bleeding disorder hemophilia B. FIX contains a Gla module, two Epidermal Growth Factor (EGF) -like modules and a serine protease region. In this thesis, studies have been …

    lund Repository record for The N-terminal EGF Module of Coagulation factor IX. Studies of Calcium Binding and Module Interactions. (opens in a new tab) Download PDF for The N-terminal EGF Module of Coagulation factor IX. Studies of Calcium Binding and Module Interactions. (opens in a new tab)

  7. ENCAPSULATION OF FACTOR IX-ENGINEERED MESENCHYMAL STEM CELLS IN ALGINATE-BASED MICROCAPSULES FOR ENHANCED VIABILITY AND FUNCTIONALITY

    … mimic their physiological extracellular matrix (ECM) environment.</p> <p>Three cell-adhesive molecules were used in this work: fibrinogen and fibronectin, two abundant proteins present in ECM, and arginine-glycine-aspartic acid (RGD) tri-peptide, the minimal essential cell adhesion peptide …

    mcmaster Repository record for ENCAPSULATION OF FACTOR IX-ENGINEERED MESENCHYMAL STEM CELLS IN ALGINATE-BASED MICROCAPSULES FOR ENHANCED VIABILITY AND FUNCTIONALITY (opens in a new tab)

  8. Characterization of Post-translational Modifications and Resulting Structure/Function Relationships of Recombinant Human Factor IX Produced in the Milk of Transgenic Pigs

    … caused by a deficiency in or dysfunction of factor IX (FIX), a complex plasma glycoprotein required for the formation and maintenance of blood clots. Treatment of hemophilia B involves infusion of replacement FIX currently derived from two sources: FIX purified from pools of human plasma …

    vt Repository record for Characterization of Post-translational Modifications and Resulting Structure/Function Relationships of Recombinant Human Factor IX Produced in the Milk of Transgenic Pigs (opens in a new tab)

  9. Hepatocyte nuclear factor 1 and the regulation of the human factor IX gene : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Molecular Biology at Massey University

    Factor IX is a serine protease involved in the mammalian blood clotting cascade. An absence of functional factor IX protease in the bloodstream results in Haemophilia B. Mutations in the regulatory region of the factor IX gene can produce a rare form of the disease called Haemophilia B Leyden. …

    massey Repository record for Hepatocyte nuclear factor 1 and the regulation of the human factor IX gene : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Molecular Biology at Massey University (opens in a new tab)

  10. Mutational analysis of the human factor IX promoter : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Genetics at Massey University

    … deficiency in the blood coagulation protein, factor IX, which is expressed primarily within the liver. Patients suffering from the Haemophilia B Leyden phenotype show a distinct pattern of factor IX expression that is characterised by severe to moderate haemophilia within children, which …

    massey Repository record for Mutational analysis of the human factor IX promoter : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Genetics at Massey University (opens in a new tab)

  11. The molecular basis of hemophilia B : identification of the defect in factor IXVancouver

    … severe hereditary disorder in which the factor IX antigen is present in relatively normal amounts but the biological activity of factor IX is markedly reduced. Previous studies have demonstrated that although the patient has 62% of the normal factor IX antigen level in his plasma, he …

    ubc Repository record for The molecular basis of hemophilia B : identification of the defect in factor IXVancouver (opens in a new tab) Download PDF for The molecular basis of hemophilia B : identification of the defect in factor IXVancouver (opens in a new tab)

  12. Mutation Analysis in Haemophilia A and Investigation of a Keratinocyte Based Gene Therapy for Haemophilia B

    … of the procoagulant function of clotting factors VIII and IX in the intrinsic coagulation pathway, respectively. The two main objectives of this project were: (I) to carry out a comprehensive search for mutations in the factor VIII gene of patients with haemophilia A and (II) to …

    glasgow Download PDF for Mutation Analysis in Haemophilia A and Investigation of a Keratinocyte Based Gene Therapy for Haemophilia B (opens in a new tab)

  13. An integrated process for the recovery of clinically significant trace proteins from human plasma

    Methods for the preparation of concentrates of factor VIII, factor IX, high purity factor IX, Cl esterase inhibitor, specific immunoglobulin and platelet factor XIII are described. These procedures were developed or modified with the aim of integration into an automated process that would allow …

    auckland-ms Repository record for An integrated process for the recovery of clinically significant trace proteins from human plasma (opens in a new tab)

  14. Upstream and downstream issues in the production of recombinant vitamin K-dependent proteins in the milk of transgenic pigs

    … therapeutic proteins, such as protein C and Factor IX, have spurred the development of recombinant DNA technology for large-scale, economically feasible production of therapeutic proteins. The mammary gland is unique in its ability to synthesize and secrete large amounts of protein into a …

    vt Repository record for Upstream and downstream issues in the production of recombinant vitamin K-dependent proteins in the milk of transgenic pigs (opens in a new tab)

  15. The role of factor VIII in blood coagulation

    <p>Factor VIII, a component of the intrinsic pathway of blood coagulation, has yet to be purified to homogeneity. It appears that, <em>in vivo</em>, the factor VIII coagulant protein is closely associated with one or more other proteins (factor VHI-related antigen and platelet aggregating factor). …

    oxford Repository record for The role of factor VIII in blood coagulation (opens in a new tab)

  16. Analysis of the molecular defects causing haemophilia B in six patients

    The factor IX genes from six haemophilia B patients were analyzed in order to determine the molecular defect responsible for causing the disease in each of the cases. Blood samples were obtained from the six patients and genomic DNA was extracted from the white blood cells. Regions of the factor IX …

    ubc Repository record for Analysis of the molecular defects causing haemophilia B in six patients (opens in a new tab) Download PDF for Analysis of the molecular defects causing haemophilia B in six patients (opens in a new tab)

  17. Improving the Safety and Efficacy of AAV Gene Therapy for Hemophilia A

    … We hypothesized that selective pressures keep factor VIII (FVIII) activity low. Using criteria established from studies of factor IX-Padua, a factor IX transgene with increased specific activity, we identified 52 amino acids we hypothesized would lead to increased FVIII activity when …

    penn Repository record for Improving the Safety and Efficacy of AAV Gene Therapy for Hemophilia A (opens in a new tab) Embargoed until 2027-02-01

  18. Moderate Heat-Assisted Gene Electrotransfer for Intradermal DNA Vaccination and Protein Replacement Therapy in the Skin

    … was repeated using a plasmid encoding Human Factor IX, the blood clotting factor defective or absent in patients with Hemophilia B. Elevated Factor IX serum protein levels were detected by ELISA up to 100 days post gene delivery. The simple engineering and safety of DNA vaccines make them an …

    odu Repository record for Moderate Heat-Assisted Gene Electrotransfer for Intradermal DNA Vaccination and Protein Replacement Therapy in the Skin (opens in a new tab)

Page 1 of 3